# INDIVIOR PHARMACEUTICALS INC (INDV)

> Institutional ownership reported to the SEC as of Q3 2026, from Form 13F filings. Source: https://holderbook.com/stocks/INDV/

- Reporting holders: 9
- Reported value: $133.9M
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [Two Seas Capital LP](https://holderbook.com/funds/1823138-two-seas-capital-lp/) | $131.6M | 3,671,072 | 1.5% | 3 |
| [Artemis Investment Management LLP](https://holderbook.com/funds/1535385-artemis-investment-management-llp/) | $1.7M | 48,231 | 0.0% | 2 |
| [SCHAPER BENZ & WISE INVESTMENT COUNSEL INC/WI](https://holderbook.com/funds/1033974-schaper-benz-wise-investment-counsel-inc-wi/) | $358.6K | 10,003 | 0.0% | 3 |
| [Farther Finance Advisors, LLC](https://holderbook.com/funds/1992825-farther-finance-advisors-llc/) | $129.9K | 3,624 | 0.0% | 3 |
| [GAMMA Investing LLC](https://holderbook.com/funds/2010235-gamma-investing-llc/) | $42.8K | 1,193 | 0.0% | 3 |
| [MassMutual Private Wealth & Trust, FSB](https://holderbook.com/funds/1103653-massmutual-private-wealth-trust-fsb/) | $6.8K | 191 | 0.0% | 3 |
| [Versant Capital Management, Inc](https://holderbook.com/funds/1735057-versant-capital-management-inc/) | $1.9K | 54 | 0.0% | 1 |
| [GILPIN WEALTH MANAGEMENT, LLC](https://holderbook.com/funds/2058144-gilpin-wealth-management-llc/) | $108 | 3 | 0.0% | 3 |
| [Davis Capital Management](https://holderbook.com/funds/1811806-davis-capital-management/) | $36 | 1 | 0.0% | 2 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q3 2026 | 9 | $133.9M |
| Q2 2026 | 340 | $5.6B |
| Q1 2026 | 292 | $3.9B |
| Q4 2025 | 260 | $4.7B |
| Q3 2025 | 202 | $2.7B |
| Q2 2025 | 122 | $1.6B |
| Q1 2025 | 117 | $867.1M |
| Q4 2024 | 114 | $976.4M |
| Q3 2024 | 102 | $728.9M |
| Q2 2024 | 97 | $1.1B |
| Q1 2024 | 90 | $1.4B |
| Q4 2023 | 74 | $992.9M |